A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
Patient who is planning to start standard-of-care AI therapy and receive treatment for at least 24 weeks. Can be planning to take AI therapy for stage 0-3 breast cancer or because they are at high risk of developing breast cancer. Concurrent gonadotropin-releasing hormone antagonist (GnRHa) therapy, anti-osteoclast therapy, anti-HER2 therapy, ribociclib, and/or PARP inhibitor are permitted
Average joint pain 0-6 on a 0-10 scale during the 7 days prior to study enrollment
Able to take oral medication
Able to read and understand English
Aware of the nature of her diagnosis, understands study requirement, and able to sign an informed consent form
You may not be if
Distant metastatic breast cancer
Current or planned use of abemaciclib during study participation
Current or planned use of chemotherapy or immunotherapy during study participation
Pregnant or breast feeding, or planning to become pregnant during study participation
Known active inflammatory bowel disease
History of colectomy and/or gastric bypass
Prior AI therapy except in the context of fertility treatment
Planned use of prebiotics during study participation
Use of estrogen supplementation other than vaginal estrogen
Receipt of another investigational agent concurrent with participation in this trial
Clareo Health | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
